Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet
This article was originally published in The Pink Sheet Daily
Executive Summary
Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.